[
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 25",
    "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list here.",
    "url": "https://finnhub.io/api/news?id=51cad26e98a55cff634e728377ee94ee04cf1e5384eb442f6922079bdc07e397",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769191913,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 25",
      "id": 138229764,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "SYK",
      "source": "SeekingAlpha",
      "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list here.",
      "url": "https://finnhub.io/api/news?id=51cad26e98a55cff634e728377ee94ee04cf1e5384eb442f6922079bdc07e397"
    }
  },
  {
    "ts": null,
    "headline": "Stryker Corp. stock underperforms Friday when compared to competitors",
    "summary": "Stryker Corp. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=d9fb78c75f911bfcd9ec2cb8c8a1f93508e681aacc15e45e3699bb2f1522f8b0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769186160,
      "headline": "Stryker Corp. stock underperforms Friday when compared to competitors",
      "id": 138235680,
      "image": "",
      "related": "SYK",
      "source": "MarketWatch",
      "summary": "Stryker Corp. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=d9fb78c75f911bfcd9ec2cb8c8a1f93508e681aacc15e45e3699bb2f1522f8b0"
    }
  },
  {
    "ts": null,
    "headline": "Oppenheimer Questions $14.5B Penumbra Deal Valuation Despite Boston Scientific’s (BSX) Mew Market Dominance",
    "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the best mid-cap growth stocks to buy right now. On January 16, Oppenheimer lowered its price target on Boston Scientific to $100 from $125 with an Outperform rating. Oppenheimer is cautious on the financial optics of Boston Scientific’s $14.5 billion acquisition of Penumbra. Although the deal creates a […]",
    "url": "https://finnhub.io/api/news?id=797b355c88d860e8fab0e814e4ed7a3c278b53653f3e5d313b4ebef4292040ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769136778,
      "headline": "Oppenheimer Questions $14.5B Penumbra Deal Valuation Despite Boston Scientific’s (BSX) Mew Market Dominance",
      "id": 138220893,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SYK",
      "source": "Yahoo",
      "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the best mid-cap growth stocks to buy right now. On January 16, Oppenheimer lowered its price target on Boston Scientific to $100 from $125 with an Outperform rating. Oppenheimer is cautious on the financial optics of Boston Scientific’s $14.5 billion acquisition of Penumbra. Although the deal creates a […]",
      "url": "https://finnhub.io/api/news?id=797b355c88d860e8fab0e814e4ed7a3c278b53653f3e5d313b4ebef4292040ab"
    }
  }
]